Clinical trials: Pharmacodynamics
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Glargine Against Insulin Aspart Infused Under the Skin in Patients With Type 2 Diabetes
This trial is conducted in Europe. The objective of the study is to investigate the effect and safety of continously basal delivered insulin aspart given by a pump versus once daily injection of insulin glargine.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00184613
- Testing
- pump, insulin glargine, insulin aspart
- Where
- Denmark
- Volunteers
- 22 people
- Sponsor
- Novo Nordisk A/S
OTC Deficiency, Ornithine Transcarbamylase Deficiency
A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD
Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.
- Conditions
- OTC Deficiency, Ornithine Transcarbamylase Deficiency, OTCD
- Trial name
- NCT06488313
- Testing
- ARCT-810
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Arcturus Therapeutics, Inc.
Healthy
Single and Multiple Ascending Doses of AZD1981 in Japan
The purpose of this study is to study safety, tolerability and pharmacokinetics of AZD1981 in healthy Japanese subjects
- Trial name
- JSAD/JMAD (NCT00698282)
- Testing
- AZD1981
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypertension
Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population
The goal of this study is to compare the characteristics of baxdrostat (CIN-107) in terms of baxdrostat levels over time in the blood in healthy Japanese and Caucasian volunteer participants.
- Trial name
- NCT05966324
- Testing
- baxdrostat
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Multiple Ascending Dose Trial of BYK324677 in Healthy Volunteers
This monocenter trial is conducted to obtain first data on safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) after multiple ascending doses of BYK324677 in humans.
- Trial name
- NCT01386541
- Testing
- BYK324677
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Nycomed
Renal Insufficiency
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function
The main objective of this study was to assess the effect of normal and impaired renal function on the safety, pharmacokinetics, and pharmacodynamics of linagliptin following oral administration of 5 mg daily for 7 days (Groups 1…
- Trial name
- NCT02191228
- Testing
- Linagliptin - single dose, Linagliptin - Multiple dose
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Neoplasms
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
The Primary purpose of this study is to identify the recommended Phase 2 dose [RP2D(s)] for JNJ-63723283 in Part 1, to assess the anti-tumor activity of JNJ-63723283 at the RP2D(s) in participants with selected advanced cancers…
- Trial name
- NCT02908906
- Testing
- JNJ-63723283
- Where
- 20 sites in United States, Moldova and 5 more
- Volunteers
- 234 people
- Sponsor
- Janssen Research & Development, LLC
Liver Cancer, Neoplasm Metastasis
A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases
The primary objective of study CT 4003 is to assess the behavior of EndoTAG®-1 in the body (making a so-called pharmacokinetic profile). Therefore, the course of the drug in the body is examined, i.e.
- Trial name
- NCT00542048
- Testing
- EndoTAG®-1
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- MediGene
Diabetes Mellitus, Type 2
Single, Ascending Dose, First Time in Human Study for GZR18 in Healthy Subjects
Single ascending dose first time in human study for GZR18 in healthy subjects
- Trial name
- NCT05328726
- Testing
- GZR-18
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Gan and Lee Pharmaceuticals, USA
Hypercholesterolemia, Healthy Volunteers
A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants
This is a single-center, randomized, double-blind, placebo-controlled, single HST101 SC dose cohort study to evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Chinese Participants with Elevated…
- Conditions
- Hypercholesterolemia, Healthy Volunteers, LDL-Cholesterol
- Trial name
- NCT06504043
- Testing
- HST101
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hasten Biopharmaceutical Co., Ltd.
Autoimmune Disease
A Study of Safety, Tolerability, PK, and PD of Subcutaneous GenSci120 in Healthy Adults.
This study is designed to evaluate the safety, tolerability, PK and PD of GenSci120 in a randomized, double-blind, placebo-controlled trial involving healthy adult participants.
- Trial name
- NCT06827457
- Testing
- GenSci120
- Where
- China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Overweight and Obesity
A Study to Investigate the Safety and Tolerability of TE-8105 in Overweight/Obese Participants Without Diabetes
This is a Phase 1/2a, first-in-human, prospective, open-label study to evaluate the safety, tolerability, PK, PD, and effect on body weight of TE-8105 in overweight/obese participants without diabetes.
- Trial name
- NCT06471530
- Testing
- TE-8105 SAD Cohort 1, TE-8105 SAD Cohort 3, TE-8105 SAD Cohort 5 (Adaptive cohort)
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Immunwork, Inc.
Systemic Lupus Erythematosus
A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects
This will be the first-in-human study designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of DS-7011a in healthy participants.
- Trial name
- NCT05203692
- Testing
- DS-7011a
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Healthy
GLPG0778: Multiple Ascending Oral Doses, Pharmacokinetic, Safety, and Pharmacodynamic Study
The purpose of the study is to evaluate the safety and tolerability of multiple ascending oral doses (MAD) of GLPG0778 given to healthy subjects for 13 days compared to placebo, and to evaluate the pharmacokinetics (PK) and…
- Trial name
- NCT01336244
- Testing
- GLPG0778
- Where
- Belgium
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Healthy
Safety, Tolerability and Pharmacodynamics of BIIF 1149 BS in Healthy Young Male Volunteers
The objective of the present study is to obtain information about the safety and tolerability of BIIF 1149 BS, to determine the pharmacologically active dose (range) by performing a citric acid challenge test and to obtain…
- Trial name
- NCT02199899
- Testing
- BIIF 1149 BS - single rising doses
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Cancer Cachexia
A First in Human Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics Effects of OC514
Oncocross is developing OC514, a drug-drug combination product containing 2 active pharmaceutical ingredients for cancer cachexia.
- Trial name
- NCT05264038
- Testing
- OC514 (Low dose), OC514 (Mid dose), OC514 (High dose)
- Where
- Australia
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Oncocross Australia Pty Ltd.
Chronic Obstructive Pulmonary Disease
Study on Single and Multiple Atomization Inhalation of HRS-9821 Suspension for Inhalation in Healthy Subjects and COPD Patients
The increased safety and tolerance of single and multiple atomized inhalation of HRS-9821 suspension for inhalation doses in healthy subjects and COPD patients.
- Trial name
- NCT05622864
- Testing
- HRS-9821
- Where
- China
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Healthy Volunteer
A Sedation/Cognition/Electroencephalogram (EEG) Study Using AZD7325 and Comparator.
The purpose of the study is to determine the effects of the compound AZD7325 as compared to lorazepam on sleepiness, concentration and brain activity.
- Trial name
- NCT00720421
- Testing
- AZD7325, Lorazepam
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Prevention of Chikungunya Virus Infection
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults
This is a Phase 1, FIH, single-center, randomized, placebo controlled, dose escalation study to evaluate the safety, tolerability, PK, and PD of mRNA-1944 in healthy adult subjects.
- Trial name
- NCT03829384
- Testing
- mRNA-1944
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Neutropenia (Low White Blood Cell Count)
A Research Study To Test How Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given By Subcutaneous Injection (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)
This is a study comparing two study drugs, Filgrastim Hospira and Neupogen®. Neupogen® is approved by the US Food and Drug Administration (FDA) to treat low numbers of specific kinds of white blood cells (WBC) known as…
- Trial name
- NCT02766647
- Testing
- Filgrastim Hospira (US), US-approved Neupogen®
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.